How to implement lung cancer screening ? In this review, we will focus on practical approaches to lung cancer screening in France and worldwide. In France, these modalities are determined by recommendations, currently in edition. However, main outcomes recommended for screening are reported here.Lung cancers screening, what methods what results? Because lung cancers are the leading cause of death from cancer, because there is effective treatment for the early stages and because it is possible to target smokers, lung cancers screening is essential. Neither chest x-ray, sputum cytology, nor blood markers are useful for this screening. Only the low-dose chest scanner had demonstrated in two randomized studies with large numbers of heavy smokers or former smokers that it significantly reduces the specific mortality from lung cancers.Risk factors and prevention of lung cancer. In France, lung cancer is the leading cause of death from cancer with more than 30,000 deaths per year. The vast majority (85%) of lung cancer are due to tobacco and the duration of smoking has a greater impact than the amount smoked. Passive smoking increases the risk of lung cancer and is responsible for around 25% of lung cancers in non-smokers in France. The risk of lung cancer linked to cannabis smoke hasn't been demonstrated, but is suspected. Other carcinogens found in certain workplaces, such as asbestos, or in the environment, such as radon in granite soils and urban air pollution, increase the risk of lung cancer. The maximum benefit on lung cancer mortality reduction should be obtained by combining smoking cessation and lung cancer screening by chest CT. Lung cancer screening has shown its effectiveness, but is currently not recommended in France. Measures to promote smoking cessation are known and include public health measures to de-normalize tobacco (neutral packaging, ban on advertising, significant increase in its price) and treatments that have been shown to be effective in smoking cessation nicotine replacement therapy, varenicline and cognitive behavioral therapy.Epidemiology of lung cancer in france and in the world. Lung cancer is the leading cause of death from cancer worldwide. In France, lung cancer is the second most common cancer in men (after prostate cancer), and the third in women (after breast and colon cancer).  https://www.selleckchem.com/products/bms309403.html  However, it ranks first among the deadliest cancers in men and second among women (after breast cancer). In the United States, mortality from lung cancer in women has exceeded mortality from breast cancer, and it is likely that this will be the case in France in a few years. The main risk factor is smoking. Although the incidence and mortality rates continue to increase in women, they remain twice higher in men compared to women. The development since the 1990s is marked by a clear increase in the incidence of adenocarcinomas in both sexes, probably linked to differences in smoking behavior.The maison des adolescents scheme (mda), 20 years already! It was created because a lot of the existing programs dedicated to teenagers and their families were unrecognized and poorly articulated. In order to make them more identifiable, Claire Brisset, défenseure des enfants (child advocate), recommended the creation of a unique place inspired by the experience of a teenager's house opened in 1999 in Le Havre. Teenagers and their families could find information and support, have their situation evaluated, offer care and be referred to other professionals if necessary. In addition to this mandate, the MDA scheme also coordinates all the different operators working in this field in their area. Today, there are 120 MDA in France. Their mission is to prevent any teenagers' malaise or angst, anywhere in France, in urban as well as in rural areas. Since the creation of the first MDA in Le Havre in 1999, the situation has improved a lot. But there is still a need to improve the territorial coverage and the financial endowment of these schemes, in order for them to be able to fulfil this beautiful ambition to better the wellbeing of France's youth.How and when to stop antiepileptic drugs? Antiepileptic drugs withdrawal can be considered in seizure-free patients with a 2-year minimum complete remission. Risk of seizure recurrence, which is related both to the epilepsy syndrome and individual characteristics, must be evaluated and may rely on the use of a computer-based risk calculator. Identifying epileptic abnormalities on EEG and cortical lesions on brain MRI could lead to reconsider drug discontinuation. Drug tapering must be progressive over 2 to 3 months, with a dose reduction every 2 weeks. Driving is not allowed during tapering and several months after withdrawal. Relapses mainly occur in the first year of withdrawal. A 2-year minimum follow-up of patients is recommended.Extra hospital use of nitrous oxide. FOR RECREATIONAL PURPOSESThe problematic recreational consumption of nitrous oxide is increasing in the adolescent population and its harms are little publicized and / or trivialized. This therefore represents a public health issue. In high doses, nitrous oxide becomes a dissociative anesthetic. It can lead to hypoxia and even asphyxia causing loss of consciousness. A chronic consumption is addictive and is characterized by megaloblastic anemia, dysfunction of the reproductive system and sensitivomotor myeloponeuropathy. After review of the previously cases, we note that the symptomatology is variable in intensity, presents a centripetal sensory impairment with dysesthesia and a deficit in the vibratory sense. Nitrous oxide alters vitamin B12 and increases the blood levels of homocysteine and methylmalonyl CoA. The magnetic resonance of the spinal cord shows abnormalities in the majority of cases. The treatment consisted of high doses of vitamin B12 for most of the cases described. In view of the good prognosis and the uncomplicated treatment, it is essential to quickly detect the impact of nitrous oxide on health.Al amyloidosis, from diagnosis to treatment. AL amyloidosis is a rare hemopathy characterized by immunoglobulin light chains deposits in almost all organs causing organ failure. The main issue is the early dia¬gnosis, which must be made in front of an unexplained non-specific symptomatology, especially cardiac or renal, in frequently elderly patients with monoclonal gammo¬pathy. Non-invasive biopsies should be made for histolo¬gical confirmation revealing positive congo red and birefringent yellow-green deposits in polarized light specific for amyloidosis. Severity is assessed by biologi¬cal markers of cardiac involvement. The treatment consists in eliminating the plasma or lympho-plasma cell dyscrasia secreting the amyloidogenic light chain, and in proposing supportive care specific to this pathology.